RxDoctor Payments DataLook up a doctor →

Anthony Pozun, DO

Interventional Cardiology · Glendale, AZNPI 1275580755

Payments from drug & device makers

$99,366in general payments, 2019–2025

Across 378 payments — averaging $262.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$78K
  • Medtronic$9K
  • Abbott$3K
  • Penumbra, Inc.$3K
  • Cvrx, Inc.$1K
  • Boston Scientific$977
  • plus $4K from 33 others

What the payments were for

  • Travel & lodging$9,3769%
  • Food & beverage$12,39912%
  • Education$10,80011%
  • Other$66,79267%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$99,366 in reported general payments places this provider in the 80th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$1,192,060
Medicare patients
917
Services billed
5,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban250$239,029
XareltoRivaroxaban224$202,707
EntrestoSacubitril/Valsartan102$104,838
JardianceEmpagliflozin41$34,166
Repatha SureclickEvolocumab18$16,128
Flecainide Acetate289$10,091
VascepaIcosapent Ethyl11$9,518
Rosuvastatin Calcium450$6,644
Metoprolol Succinate589$5,373
Ranolazine ErRanolazine35$4,822
Spironolactone765$4,810
ClopidogrelClopidogrel Bisulfate397$4,236
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide182$4,068
Isosorbide Dinitrate98$3,562
Midodrine Hcl67$3,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$239,029250 claims
Johnson & JohnsonXarelto$388$202,707224 claims
NovartisEntresto$330$104,838102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →